MD Anderson Cancer Center and other Texas Medical Center-based specialty facilities will provide resources for Aethlon Medical to conduct clinical investigations for Hemopurifier therapy, the company announced in a press release.
The Hemopurifier is a first-in-class therapeutic device that targets the rapid elimination of circulating viruses and tumor-secreted exosomes that suppress cancer patients’ immune system.
Led by Dr. Stephen Z. Fadem, co-medical director of DaVita MedCenter Dialysis, Aethlon will treat ten end-stage renal disease (ESRD) patients infected with the Hepatitis C virus to demonstrate the safety of Hemopurifier therapy. If the feasibility study is successfully completed, Aethlon will then conduct pivotal studies required for market clearance to treat hepatitis C and potentially other disease indications.
The California-based company, which is working to develop selective therapeutic filtration devices that can help treat life-threatening diseases and conditions such as cancer, signed an agreement with Minneapolis-based DaVita Clinical Research (DCR) to provide clinical management services to support the forthcoming feasibility study of the device.
The clinical trial will be conducted by Dr.Fadem in the DaVita MedCenter Dialysis in Houston, one of the three largest dialysis centers in the country with 72 treatment stations.
The central location in Houston, the proximity to MD Anderson Cancer Center, and other adequate spaces located within the Texas Medical Center all combine to represent a “unique location to conduct future clinical investigations of the Hemopurifier device in a variety of life-threatening health conditions,” stated Aethlon Medical CEO Jim Joyce.
Dr. Fadem, who also serves as the Chief Medical Officer at Kidney Associates and the Medical Director for the Houston Kidney Center Integrated Service Network at DaVita Kidney Care, completed a renal fellowship at the University of Texas Health Science Center in San Antonio. He is a graduate of the University of Oklahoma College of Medicine, and completed his internal medicine residency at The University of Texas and MD Anderson Hospital in Houston. He is a Clinical Professor of Medicine at Baylor College of Medicine.